Tris Pharma partners with Braingaze to launches digital health business

Tris Pharma, a prominent biopharmaceutical company with a focus on attention deficit hyperactivity disorder (ADHD), pain management, addiction, and neurological disorders, has recently embarked on a significant venture. This venture involves the establishment of Tris Digital Health in collaboration with Braingaze Ltd., a notable player in the digital health sector. Tris Digital Health's primary objective is the development and commercialization of digital diagnostic and therapeutic products tailored specifically for neurological health conditions.

In a strategic move, Tris Pharma has secured exclusive rights to Braingaze’s cutting-edge digital ADHD diagnostic platform for distribution in the United States and Canada. This platform, already carrying the European CE Mark as a medical device, is poised to undergo further validation through clinical trials overseen by the U.S. Food and Drug Administration (FDA). These trials are intended to confirm the platform's efficacy as an objective diagnostic tool for ADHD within clinical settings in both the U.S. and Canada.

Ketan Mehta, the visionary founder and CEO of Tris Pharma, underscores the pressing need for more accurate ADHD diagnostic tools. He expresses confidence in Tris Digital Health's ability to address this need and is enthusiastic about the collaboration with Braingaze. Mehta views this partnership as a significant step forward in advancing healthcare solutions beneficial to physicians, ADHD patients, and caregivers alike.

Echoing Mehta's sentiments, Laszlo Bax, CEO and co-founder of Braingaze, emphasises the positive reception of their diagnostic test by European physicians. Bax is eager to extend the reach of their innovative ADHD diagnostic solutions to patients in the United States and Canada. He views Tris Pharma, with its extensive experience and successful track record in the ADHD domain, as an ideal partner to facilitate this expansion and ensure the widespread adoption of their technology.

Click here to read the original news story.